Adjustable Electric Drive Based on Radiation-Resistant Induction Motors

The object under consideration is an adjustable electric drive based on radiation-resistant DAR induction motors with a power of 0.75 kW and 2.2 kW, with a nominal stator field rotation speed of 1000 rpm and 1500 rpm and an environmental protection method IP 68, designed to use in the equipment for hydrometallurgical processing of spent nuclear fuel (SNF) of the processing module of the pilot demonstration energy complex (PM PDEC). Bench tests of DAR prototypes confirmed that the developed motors in accordance with electromagnetic parameters, energy and starting characteristics fully comply with serial asynchronous motors of similar power and speed and satisfy the requirements of the technical specifications. The control system with the Altivar ATV212/ATV320 frequency converter ensures stable operation of the DAR in the range of 1:50 speed control in the "sensorless"version, the functions and interface of the control system meet the specified requirements. Recommendations are given on expanding the tasks of automation of the technological process, which can be provided by means of the developed control system based on software implementation. An assessment of the thermal state during liquid cooling of engines during operation from the control system. © Published under licence by IOP Publishing Ltd

THE OXIDATIVE METABOLISM DISORDERS IN PATIENTS SUFFERING FROM TYPE II DIABETES MELLITUS AND DISEASES OF THE RESPIRATORY APPARATUS

In the present research the changes in the enzyme link of the antioxidative system as well as in the content of reduced erythrocyte glutathione and the oral liquid in patients suffering from type II diabetes mellitus, bronchial asthma, chronic obstructive lungs disorder and comorbidities of the researched diseases have been disclosed. The regularities in changes of the biochemical indices on the systemic and the local level have been revealed. As a rule in patients suffering from the pathology comorbidities the more apparent metabolic disorders have been indicated. The most essential changes in the erythrocyte suspension have been revealed in patients suffering from all the pathologies found three. The activity of superoxide dismutase has increased by 29 %, of catalase by 65 %, of glutathione reductase by 2,4 times while the activity of glutathione peroxidase has decreased by 3,3 times. The glutathione concentration in the same patient group has been 19 % down from the control indices. In the oral liquid of the same group the activity of superoxide dismutase as well as the one of glutathione reductase has increased by 81 % and 83 % respectively. The activity of glutathione peroxidase has not changed, the activity of catalase has decreased by 9,2 times. In general, the indices of patients suffering from the comorbidities have been closer to the pathologies of the respiratory system which proves the conception of the leading role of oxidative disorders in such patients

EFFICIENCY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY DEPENDING ON THE POLYMORPHISM OF CYP2C9 GENE

Aim. To assess the efficiency of combined antihypertensive therapy in patients with arterial hypertension and obesity depending on the polymorphism of CYP2C9 gene.Materials and methods. Patients with uncontrolled arterial hypertension (1-2 stage) and obesity were included in our study. They were randomized by the method of "converts" into two groups: the first group (n=70) took the fixed-dose combinations of the valsartan and amlodipine and the second group took the fixed-dose combinations of the perindopril and amlodipine. Blood pressure of all patients was measured according to the recommendation for diagnosis and treatment of arterial hypertension (ESH/ESC, 2013) before and after 8 weeks of the initial treatment. All tested people had venous blood sampling succeeded by DNA extraction and amplification in real time mode polymorphic variants CYP2C9 gene. The improvement of health self-esteem by QALY was determined like increase of index from initial by 10 % and more.Results. It is shown that people with heterozygosis polymorphisms *1/*2 and *1/*3 reached the target level of arterial blood pressure after 8 weeks of combined therapy of valsartan and the amlodipine (93,1% against 57,1% respectively). In addition to the above, the frequency of reaching the target level of the arterial blood pressure in the group of tested people who get angiotensin II receptor blocker and calcium-channel blocker was for certain higher among the patients with polymorphisms *1/*2 and *1/*3 in comparison with the polymorphic variants CYP2C9 gene (91,3% against 57,1% respectively). The improvement of the health self-esteem by QALY of the tested patients with polymorphisms *1/*2 and *1/*3 CYP2C9 gene is seen more often between the patients of the first group than between patients of the second group (95,6% against 66,7% respectively).Conclusion. Determined interrelation between the efficiency level of the combined antihypertensive therapy with the CYP2C9 gene polymorphism can be considered in cases of insufficient effect of assigned therapy or the uncontrolled character of the arterial hypertension. In our opinion, appropriate personalized correction of therapy will contribute to its optimization relating to the patients with arterial hypertension and obesity

Small Molecules Dorsomorphin and LDN-193189 Inhibit Myostatin/GDF8 Signaling and Promote Functional Myoblast Differentiation.

GDF8, or myostatin, is a member of the TGF-β superfamily of secreted polypeptide growth factors. GDF8 is a potent negative regulator of myogenesis both in vivo and in vitro. We found that GDF8 signaling was inhibited by the small molecule ATP competitive inhibitors Dorsomorphin and LDN-193189. These compounds were previously shown to be potent inhibitors of BMP signaling by binding to the type BMP type I receptors ALK1/2/3/6. We present the crystal structure of the type II receptor ActRIIA with dorsomorphin, and demonstrate that dorsomorphin or LDN-193189 target GDF8 induced Smad2/3 signaling and repression of myogenic transcription factors. As a result, both inhibitors rescue myogenesis in myoblasts treated with GDF8. As revealed by quantitative live cell microscopy, treatment with dorsomorphin or LDN-193189 promoted the contractile activity of myotubular networks in vitro. We therefore suggest these inhibitors as suitable tools to promote functional myogenesis